Association between IRS-2 G1057D polymorphism and risk of gastric cancer.

Xiao-Mei Zhao,Jie Chen,Li Yang,Xuan Luo,Lin-Lin Xu,Dong-Xiao Liu,Su-Lan Zhai,Ping Li,Xue-Rong Wang
DOI: https://doi.org/10.4251/wjgo.v4.i1.9
2012-01-01
World Journal of Gastrointestinal Oncology
Abstract:AIM: To investigate the relationship between insulin receptor substrate-2 (IRS-2) G1057D polymorphism and the risk of gastric cancer (GC) in a Chinese population. METHODS: A case-control study with 197 GC patients and 156 age-and sex-matched control subjects was conducted. The genotypes of polymorphism were assessed by polymerase chain reaction-restriction fragment length polymorphism. RESULTS: The genotype frequencies of IRS-2 G1057D polymorphism in cases were obviously different from those in the control group (P = 0.031). Compared with GG genotype carriers, the risk for GC was significantly higher (adjusted odds ratio = 2.32, 95% CI: 1.03-5.23, P = 0.042) in the individuals with the IRS-2 DD genotype. Furthermore, stratified analysis was performed based on age, sex, smoking status and residence, but no significant difference between the two groups was found. In addition, no significant association between genotypes and clinicopathological features was observed either. CONCLUSION: This study demonstrates that IRS-2 G1057D is involved in susceptibility to GC, although further large-sample studies are still needed. (C) 2012 Baishideng. All rights reserved.
What problem does this paper attempt to address?